Shares of KemPharm Inc (NASDAQ:KMPH) have earned an average rating of “Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $9.25.
KMPH has been the topic of several recent research reports. ValuEngine upgraded shares of KemPharm from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd. Zacks Investment Research upgraded shares of KemPharm from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research report on Wednesday, November 15th. Finally, Royal Bank of Canada set a $9.00 price target on shares of KemPharm and gave the stock a “buy” rating in a research report on Tuesday, January 16th.
KemPharm (KMPH) opened at $6.00 on Tuesday. The company has a debt-to-equity ratio of -1.92, a current ratio of 7.56 and a quick ratio of 7.56. KemPharm has a 52-week low of $2.45 and a 52-week high of $6.75. The firm has a market cap of $87.94 and a P/E ratio of -2.05.
In other KemPharm news, EVP Daniel L. Cohen purchased 7,500 shares of the firm’s stock in a transaction on Monday, November 27th. The shares were acquired at an average cost of $3.79 per share, for a total transaction of $28,425.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 25.40% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Victory Capital Management Inc. raised its position in shares of KemPharm by 26.7% during the 4th quarter. Victory Capital Management Inc. now owns 162,077 shares of the specialty pharmaceutical company’s stock valued at $656,000 after purchasing an additional 34,114 shares during the period. C WorldWide Group Holding A S raised its position in shares of KemPharm by 14.1% during the 3rd quarter. C WorldWide Group Holding A S now owns 435,528 shares of the specialty pharmaceutical company’s stock valued at $1,611,000 after purchasing an additional 53,829 shares during the period. Finally, Alyeska Investment Group L.P. raised its position in shares of KemPharm by 1.8% during the 3rd quarter. Alyeska Investment Group L.P. now owns 992,338 shares of the specialty pharmaceutical company’s stock valued at $3,672,000 after purchasing an additional 17,721 shares during the period. Institutional investors and hedge funds own 36.45% of the company’s stock.
TRADEMARK VIOLATION WARNING: “KemPharm Inc (KMPH) Given Average Rating of “Buy” by Analysts” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/13/kempharm-inc-kmph-given-average-rating-of-buy-by-analysts.html.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.